St. Jude and Mustang Bio enter into exclusive worldwide license agreement

A partnership between St. Jude and Mustang Bio may change the challenges faced by those diagnosed with what is commonly referred to as “bubble boy disease.” Memphis' St. Jude Children’s Research Hospital and New York-based Mustang Bio Inc. have entered into an exclusive worldwide license agreement to develop a first-in-class gene therapy for X-linked severe combined immunodeficiency (X-SCID). The rare and sometimes fatal dis ease affects one in every 50,000 to 100,000 newborns and is the most…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news